Miamind was there! At the world’s largest medical technology trade fair MEDICA in Düsseldorf, we showcased our innovative, personalized neurostimulator to an international audience of manufacturers, distributors, medical professionals, hospital operators, investors, journalists, and patients. Among more than 5,000 exhibitors from 70 countries, our technology was a true highlight – and for good reason.
MEDICA 2025: Experience the Future of Medicine Up Close
The MEDICA is not just an ordinary trade fair. It is the global showcase for medical technology and health innovation. With over 80,000 visitors and exhibitors from around the world, Düsseldorf transforms into an international hospital of the future for four days.
This framework provided us with the perfect opportunity to demonstrate what personalized, non-invasive brain stimulation can truly achieve – and how it can change the lives of patients with stroke, Alzheimer’s, dementia, and other neurocognitive disorders.
The significance of the event is underscored by the fact that the German Federal Minister of Health, Nina Warken, visited Miamind’s booth at the opening of MEDICA – a clear signal of the importance of innovative neurotechnology in health policy.
Miamind in Focus: A Helmet for Improving Symptoms of Degenerative Conditions
Our Miamind® Neurostimulator generated substantial interest. The custom-made helmet, produced by a 3D printer and equipped with up to 32 electrodes, is more than just technology – it represents personalized precision medicine.
Further Information & Media Reports
Sat1 News
At the MEDICA trade fair in Düsseldorf, high-tech devices are showcased that look like they belong in an action movie – such as 3D electrode helmets or a robotic arm for ultrasound.
WDR News
A Swiss helmet is designed to assist people with Alzheimer’s or the effects of a stroke. It emits mild electrical impulses that can alleviate motor issues.
RTL News
The world's largest medical trade fair kicked off in Düsseldorf on Monday (November 17). Over 5,000 exhibitors provide insights into the healthcare of tomorrow.
How does Miamind work?
“We stimulate the neurons,” explained Alois Hopf, neuroscientist and Chief Scientific Officer (CSO) of Bottneuro AG. “This means we can increase activity, leading to targeted improvements in cognitive performance, as well as motor skills, depending on the areas that are stimulated. We can thus induce specific electrical activities.”
This is the crucial difference compared to standardized neurostimulation methods: Each Miamind neurostimulator is fully personalized based on an MRI scan of the patient and 3D printed. The electrodes are positioned exactly where they are supposed to have therapeutic effects.
Home therapy instead of clinic visits
Another significant advantage we highlighted at MEDICA: Miamind enables therapy at home.
“Previously, one had to go to a clinic for treatment,” said Thomas Hefti, CEO of Bottneuro AG, “now it can also be done at home.”
This significantly improves the quality of life for patients and their families. Therapy sessions last about an hour and can take place in a familiar environment. Doctors supervise the treatment through regular application protocols. Practical and dignified at the same time.
Realistic expectations, real results
Dr. Hopf also made clear what realistic hopes patients can have – and where the limits lie:
“We cannot reverse degeneration that has already occurred. We can utilize existing potential and ideally influence the course of the disease, but not reverse it.”
A trend at MEDICA: High-tech for home
Miamind fits well into a larger trend that was clearly highlighted at MEDICA 2025: medical technology that people can use in their own homes. In addition to our neurostimulator helmet, exhibitors also presented wrist blood pressure monitors, smart fall sensors with airbags for seniors, and other practical solutions for everyday life.
The message is clear: The future of medicine is decentralized, personalized, and patient-centered.
Why Miamind is unique
- Complete personalization – Each device is tailored to the patient’s anatomy and medical condition
- MRI-based precision – Electrode positions are calculated from brain scans
- Integrated EEG monitoring – Real-time monitoring of therapeutic effects
- Home therapy with medical supervision – Flexibility without loss of quality
- Registered with Swissmedic, MHRA, and EU as a customized product under MDR
What’s next?
At MEDICA, Miamind attracted significant interest from professionals and casual visitors who recognized the potential of personalized brain stimulation. We are currently in an exciting phase:
- Further clinical studies are planned
- We are gradually expanding our treatment network
- Interested patients already have access to therapy with a prescription from a specialist
- We are working on international partnerships to enhance availability
Conclusion: Innovation that resonates
MEDICA 2025 showed that there is a strong appetite for innovative solutions for stroke, Alzheimer’s, dementia, and other neurodegenerative diseases.
Miamind proves: personalized, non-invasive brain stimulation is no longer a vision of the future – it is now.
We are proud to have made an important contribution to the future of neurological therapy at the world’s largest medical trade fair.
About Bottneuro AG
Bottneuro develops and markets the Miamind® Neurostimulator – an innovative, MRI-based solution for personalized transcranial electrical stimulation. The company, based in Basel, Switzerland, focuses on the development of non-invasive treatments for neurodegenerative diseases.
Interested in Miamind?
Patients and relatives who are interested in therapy or need more information can contact their treating physician. Physicians and clinics are welcome to reach out to us directly.